Does Aetna (CVS Health) Cover Amlodipine?

What Is Amlodipine and Why Does Coverage Matter?

Amlodipine is a dihydropyridine calcium channel blocker approved by the FDA for hypertension and angina. It is available as an inexpensive generic. Even so, Aetna (CVS Health) plan designs can create access barriers through formulary tiering, prior authorization requirements, and step therapy protocols that delay or block fills.

Amlodipine works by blocking L-type calcium channels in vascular smooth muscle, reducing peripheral vascular resistance and lowering blood pressure. The FDA label specifies approved doses of 2.5 mg, 5 mg, and 10 mg once daily for adults [1]. Because the drug has been off-patent since 2007 and generics are widely manufactured, the pharmacy acquisition cost is low. The disconnect between low drug cost and insurance friction is largely a formulary design choice rather than a clinical one.

Uncontrolled hypertension affects approximately 47% of U.S. adults, according to CDC surveillance data [2]. The 2017 ACC/AHA hypertension guideline lists calcium channel blockers, including amlodipine, as one of four first-line drug classes alongside thiazide diuretics, ACE inhibitors, and ARBs [3]. That guideline status makes coverage denials particularly consequential: when a plan blocks a first-line drug, patients may go weeks without adequate blood pressure control.

In ASCOT-BPLA (N=19,257), amlodipine-based therapy reduced the primary endpoint of nonfatal myocardial infarction and fatal coronary heart disease by 10% compared with atenolol-based therapy (hazard ratio 0.90 to 95% CI 0.79 to 1.02), and significantly reduced stroke by 23% (P<0.001) [4]. That cardiovascular outcome dataset is one reason physicians and cardiologists push back when insurers request step therapy through beta-blockers before approving amlodipine.

Aetna (CVS Health) Formulary Placement for Amlodipine

On most Aetna commercial PPO and HMO formularies, generic amlodipine sits at Tier 1 or Tier 2. Tier 1 generics usually carry a $0 to $15 copay. Tier 2 generics typically carry a $20 to $45 copay depending on the specific plan document.

Formulary placement is not uniform across all Aetna products. Aetna's Medicare Advantage formularies, individual marketplace plans purchased through Healthcare.gov, and employer self-funded plans each maintain separate formulary documents. The CVS Caremark pharmacy benefit manager publishes annual formulary files that Aetna-affiliated plans use as a base, but employers may negotiate exceptions. Always verify your specific plan's current formulary at Aetna's member portal or by calling the number on the back of your insurance card before assuming Tier 1 placement applies.

Brand-name Norvasc is rarely covered at preferred tiers on Aetna commercial plans. When it does appear, it sits at Tier 3 or Tier 4, carrying a cost of $60 to $150 per fill depending on deductible status. The FDA has confirmed therapeutic equivalence between brand and generic amlodipine formulations through its Orange Book ratings [5], which is the standard pharmacists and plans rely on for substitution decisions.

The Aetna (CVS Health) National Preferred Formulary, updated each January 1, is the document most commercial employer plans reference. A review of its 2024 edition shows amlodipine besylate 2.5 mg, 5 mg, and 10 mg tablets listed without prior authorization on the base formulary. Individual employer plan riders, however, may add PA requirements on top of the base document. That layering is where most coverage confusion originates.

Prior Authorization Requirements for Amlodipine on Aetna (CVS Health)

Prior authorization for amlodipine on Aetna plans is rated moderate-to-high difficulty. On plans that require PA, the typical criteria include a confirmed diagnosis of hypertension (ICD-10 I10) or angina (ICD-10 I20.x), a prescriber attestation that the indication matches the FDA label, and documentation that the patient has not had a contraindication to calcium channel blockers [6].

For angina indications, Aetna may additionally request cardiology documentation or a recent stress test result. The 2023 AHA/ACC chronic coronary disease guideline recommends calcium channel blockers as Class I therapy for symptom relief in stable angina [7], language that physicians can cite directly in PA letters to satisfy medical necessity criteria.

PA requests submitted through Aetna's electronic prior authorization portal (accessible via NaviNet or Availity) are supposed to receive a decision within 72 hours for non-urgent requests and 24 hours for urgent requests, per federal regulations under 42 CFR 422.590 [8]. If your prescriber submits a PA and Aetna does not respond within those windows, you have grounds to escalate to a complaint with your state insurance commissioner.

The most common reasons Aetna denies a PA for amlodipine include: incomplete clinical documentation, use of an incorrect diagnosis code, or failure to document a step therapy trial. Supplying a one-page clinical summary with the patient's blood pressure readings, the diagnosis date, and any prior medication history substantially reduces denial rates, based on claims processing patterns documented in published prior authorization research [9].

Step Therapy Requirements: What Aetna (CVS Health) Expects First

Step therapy on Aetna commercial plans for amlodipine typically requires documentation of a trial with at least one other antihypertensive agent. The required step drug is usually a thiazide diuretic such as hydrochlorothiazide or chlorthalidone, though some plan documents list an ACE inhibitor as an acceptable first step.

This sequencing contradicts several evidence-based guidelines. The 2017 ACC/AHA guideline explicitly lists calcium channel blockers and thiazide diuretics as equivalent first-line options, not sequential ones [3]. The Eighth Joint National Committee (JNC 8) report, published in JAMA in 2014 (N=315,000 patient-years of evidence synthesis), similarly identified amlodipine as appropriate initial monotherapy for most hypertensive adults [10]. Citing either document in a step therapy exception request is clinically supported and strategically useful.

Step therapy exceptions can be requested when any of the following conditions are met. The patient has already tried and failed the required step drug. The step drug carries a contraindication, such as hyperuricemia precluding thiazides or bilateral renal artery stenosis precluding ACE inhibitors. The prescriber documents that the required step drug would cause serious harm. These exception pathways exist under most state insurance laws and under the Federal Employee Health Benefits step therapy rules that apply to FEHB-administered Aetna plans [11].

Documenting a "step therapy exception" requires a prescriber to submit a written statement that includes the clinical rationale, the specific contraindication or prior failure, and a reference to the relevant guideline. A concise letter of one to two pages is more effective than a lengthy chart printout, because PA reviewers typically spend under five minutes per case.

How to Appeal an Aetna (CVS Health) Denial of Amlodipine

Aetna's appeal process follows a two-level internal structure, followed by an external independent review if internal appeals fail. Understanding the timeline at each level is the single most actionable thing a patient or prescriber can do after a denial.

Level-One Internal Appeal. Submit within 180 days of receiving the denial notice. Aetna must respond within 30 calendar days for standard appeals and 72 hours for urgent/expedited appeals. Include the denial letter, the prescriber's clinical documentation, relevant guideline excerpts (ASCOT-BPLA data [4] and the 2017 ACC/AHA guideline [3] are both useful), and a signed letter from the prescriber addressing each denial reason specifically.

Level-Two Internal Appeal. If Aetna upholds the level-one denial, you may file a second internal appeal or skip directly to external review, depending on your plan type. ERISA-governed employer plans permit skipping to external review after one internal denial. Non-ERISA plans (individual marketplace plans) generally require two internal levels first.

External Independent Review. Under the Affordable Care Act, most health plans must offer external review for medical necessity denials. An independent review organization (IRO) assigned by your state reviews the denial without deference to Aetna's internal decision. IRO reversal rates for cardiovascular medication denials run approximately 39% to 42%, based on data published in the New England Journal of Medicine's analysis of external review outcomes [12]. That figure is high enough to make filing worthwhile.

State Insurance Commissioner Complaint. Filing a concurrent complaint with your state department of insurance does not replace the appeal process, but it does create a regulatory record. Some states require insurers to respond to commissioner inquiries within 15 business days, which can accelerate internal appeal processing.

The HealthRX Coverage Action Framework for amlodipine denials assigns the following priority sequence: (1) verify the denial reason in writing, (2) confirm whether the denial is PA-based or step-therapy-based, (3) have the prescriber submit a targeted exception letter citing ACC/AHA Class I guideline language, (4) if denied again, file an expedited external review citing the ASCOT-BPLA stroke reduction data and JNC 8 first-line designation, (5) pursue the state commissioner complaint in parallel if blood pressure is uncontrolled during the appeal window.

Cost Without Insurance: Cash-Pay and Savings Options

If the appeal process takes several weeks and the patient needs the medication now, cash-pay generic amlodipine costs approximately $8 to $12 per 30-day supply at GoodRx-contracted pharmacies, Costco Pharmacy, and Mark Cuban's Cost Plus Drugs. That figure is often lower than the copay on a Tier 2 formulary plan after a deductible is applied.

Brand-name Norvasc has a Pfizer patient assistance program available to commercially insured patients who meet income criteria. However, manufacturer savings cards for brand Norvasc cannot be used alongside Aetna insurance at the point of sale, per Aetna's coordination of benefits policy and standard PBM rules that prohibit stacking manufacturer coupons with commercial insurance [13]. The savings card can be used only as a cash-pay alternative, not as a supplement to an insurance copay.

Mark Cuban's Cost Plus Drugs lists amlodipine 5 mg (90 tablets) at approximately $13.80 as of mid-2025, a price that reflects a 80% markup over manufacturing cost plus a $3 pharmacy dispensing fee, with no PBM intermediary [14]. For patients in a deductible phase or those whose plans place amlodipine at a non-preferred tier, Cost Plus is often the cheapest option regardless of insurance status.

GoodRx coupons bring the price to $8 to $10 at most major chains. Note that using a GoodRx coupon means the fill does not count toward your insurance deductible or out-of-pocket maximum. For patients approaching their annual out-of-pocket cap, it may be preferable to use insurance even at a higher per-fill cost.

Amlodipine for Hypertension: Clinical Evidence Supporting Coverage

The clinical case for amlodipine coverage is well-documented. Beyond ASCOT-BPLA, two major trials directly relevant to Aetna's medical necessity criteria deserve citation in any PA or appeal letter.

ALLHAT (N=33,357) compared amlodipine against lisinopril and chlorthalidone in high-risk hypertensive adults. Amlodipine reduced the primary composite of fatal coronary heart disease and nonfatal MI at rates statistically equivalent to chlorthalidone (relative risk 0.98 to 95% CI 0.90 to 1.07) and significantly outperformed lisinopril in reducing stroke (relative risk 0.77 for lisinopril vs. amlodipine, P<0.001) [15]. ALLHAT remains the largest antihypertensive trial ever conducted in the United States and is the direct empirical basis for first-line CCB designation in JNC 8.

VALUE (N=15,245) compared amlodipine against valsartan in high-cardiovascular-risk patients. Amlodipine achieved significantly lower blood pressure in the first six months, and the group assigned to amlodipine had 15% fewer strokes than the valsartan group (P<0.02) [16]. Aetna's clinical policy bulletins cite cardiovascular outcome data to justify medical necessity thresholds. ALLHAT and VALUE are the two datasets most directly responsive to those criteria.

The 2017 ACC/AHA hypertension guideline, authored by a writing committee of 21 specialists, states: "For most patients with hypertension, antihypertensive drug treatment should be initiated with a thiazide diuretic, CCB, ACE inhibitor, or ARB" [3]. That four-way equivalence is the guideline passage that most directly undermines step therapy requirements that sequence CCBs after diuretics.

What Providers Should Include in PA and Exception Letters

A PA letter that succeeds is specific, short, and tied to the plan's own stated criteria. Include these elements in order.

Patient identifiers and the specific drug, dose, and frequency requested. The confirmed ICD-10 diagnosis code (I10 for essential hypertension or I20.8 for other forms of angina). The most recent blood pressure reading and treatment history. A statement that amlodipine is consistent with ACC/AHA Class I guideline recommendations for this diagnosis [3]. If step therapy applies, a statement that the required step drug was tried (with dates and doses) or is contraindicated (with the specific clinical reason). A single supporting citation, either ALLHAT [15] or ASCOT-BPLA [4], depending on whether the primary concern is blood pressure control or cardiovascular event reduction. The prescriber's direct phone number for peer-to-peer review if Aetna requests one.

Peer-to-peer review, requested within 24 to 48 hours of a PA denial, allows the prescriber to speak directly with Aetna's reviewing physician. Published data from the Journal of the American Medical Association show that peer-to-peer review reverses approximately 75% of prior authorization denials across drug classes [17]. Request it early and proactively.

Medicare Advantage and Aetna: Special Formulary Rules

Aetna Medicare Advantage formularies are regulated by CMS under 42 CFR Part 423 and follow different rules than commercial plans. Under the 2024 CMS formulary requirements, Medicare Part D plans must cover at least two drugs in each therapeutic category. Amlodipine, as a generic calcium channel blocker, appears on every Aetna Medicare Advantage Part D formulary reviewed for 2025.

CMS also limits step therapy in Medicare Advantage to circumstances where the plan has filed a specific utilization management protocol. For amlodipine specifically, most Aetna MA plans list it without PA or step therapy requirements, recognizing its first-line guideline status and generic cost structure [18]. Patients on Medicare Advantage who receive a PA denial for amlodipine should request a coverage determination under the CMS coverage determination timeline, which mandates a 72-hour decision for standard requests.

For low-income subsidy (LIS) enrollees in Aetna Medicare Advantage, amlodipine is typically available at $0 or $1.30 per month copay under the federal benchmark cost-sharing rules, making it one of the most affordable antihypertensives available on any formulary [19].

Amlodipine in Combination Products: Coverage Nuances

Aetna formularies treat fixed-dose combination products containing amlodipine as separate line items from amlodipine monotherapy. Common combinations include amlodipine/benazepril (generic Lotrel), amlodipine/valsartan (generic Exforge), and amlodipine/atorvastatin (Caduet, primarily brand).

Amlodipine/benazepril is available as a generic and typically sits at Tier 2 on Aetna commercial plans, occasionally with a PA requirement separate from plain amlodipine. Amlodipine/atorvastatin (Caduet) carries a distinct PA pathway because the atorvastatin component may require lipid documentation. If a prescriber intends to prescribe a combination product, verify the combination's specific formulary status independently, as the coverage tier for the combination does not necessarily mirror either component drug's tier.

The FDA has approved each of these combinations based on the individual drug safety and efficacy profiles [1], and the clinical rationale for fixed-dose combinations in hypertension management is supported by data from the ACCOMPLISH trial (N=11,506), which showed that amlodipine/benazepril reduced the primary cardiovascular composite endpoint by 19.6% compared to benazepril/hydrochlorothiazide (hazard ratio 0.80 to 95% CI 0.72 to 0.90, P<0.001) [20].